psalexa
logo

Onychomycosis Therapeutics Pipeline Analysis

Onychomycosis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11256
Available Format:

Onychomycosis is also known as fungal nail infections, caused by yeasts, particularly Trichophyton rubrum and Trichophyton mentagrophytes. Peoples having weak immune system are more susceptible to the disease. Onychomycosis is classified into four types, distal subungual onychomycosis, proximal subungual onychomycosis, white superficial onychomycosis and candida infections of the nail. There are some risk factors associated with onychomycosis such as diabetes and peripheral artery disease, psoriasis, wearing tight shoes, weakened the immune system, damaged nails, athlete’s foot and frequent contact with fungi. Diabetic foot syndrome or diabetic foot ulcer is the severe complications of onychomycosis in diabetic patients. Moberg Pharma AB is in the process of developing MOB-015 as a squalene monooxygenase inhibitor for the treatment of onychomycosis. Hallux, Inc. is in the process of developing HTS-519 as a squalene monooxygenase inhibitor for the treatment of onychomycosis. Some of the companies/universities having the pipeline of onychomycosis include Moberg Pharma AB, Hallux, Inc., Western University of Health Sciences, and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry